Načítá se...
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab
Approximately 20% of breast cancer patients harbor tumors that overexpress human epidermal growth factor receptor 2 (HER2; also known as ErbB2), a receptor tyrosine kinase that belongs to the epidermal growth factor receptor family of receptor tyrosine kinases. HER2 amplification and hyperactivation...
Uloženo v:
| Vydáno v: | Cancer Manag Res |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4762586/ https://ncbi.nlm.nih.gov/pubmed/26937204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S55279 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|